Safety and efficacy of low-dose esterified estrogens and methyltestosterone, alone or combined, for the treatment of hot flashes in menopausal women: a randomized, double-blind, placebo-controlled study.

Abstract

This study evaluated safety and efficacy of esterified estrogens and methyltestosterone administered alone or in combination for the treatment of hot flashes in menopausal women. The 0.30-mg esterified estrogens and 0.30-mg methyltestosterone combination was the lowest effective dose, and our results are consistent with the known safety profile of estrogen and androgen combination products.

• Authors: James Liu, Adam Allgood, Leonard R Derogatis, Stephen Swanson, Michael O'Mahony, Bertrand Nedoss, Herbert Soper, Edward Zbella, Svetlana Vladimirovna Prokofieva, Lisa Zipfel, Chun-Yuan Guo
• Journal: Fertility and sterility (Fertil Steril) Vol. 95 Issue 1 Pg. 366-8 (Jan 2011) ISSN: 1556-5653 [Electronic] United States
• PMID: 20850731 (Publication Type: Journal Article, Randomized Controlled Trial)
• Copyright: Copyright © 2011 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Chemical References

• Anabolic Agents
• Estrogens
• Estrogens, Esterified (USP)
• Placebos
• Methyltestosterone

Topics

• Anabolic Agents (administration & dosage, adverse effects)
• Dose-Response Relationship, Drug
• Double-Blind Method
• Drug Therapy, Combination
• Estrogen Replacement Therapy (methods)
• Estrogens (administration & dosage, adverse effects)
• Estrogens, Esterified (USP) (administration & dosage, adverse effects)
• Female
• Hot Flashes (drug therapy)
• Humans
• Menopause (drug effects)
• Methyltestosterone (administration & dosage, adverse effects)
• Placebos
• Severity of Illness Index
• Treatment Outcome